Valuation : HighTide Therapeutics, Inc.

Market Cap 1.51B 1.76B 224M 193M 182M 166M 310M 21.19B 311M 2.15B 833M 10.87B 843M 824M 35.02B P/E 2024
-1.41x
P/E 2025 -5.19x
Enterprise Value 1.13B 1.32B 168M 145M 136M 125M 233M 15.9B 234M 1.61B 625M 8.16B 632M 619M 26.28B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
63.21%
Yield 2024 *
-
Yield 2025 -
1 week+0.33%
Current month-3.14%
1 month-0.65%
3 months-0.32%
6 months+62.11%
Current year+4.41%
1 week 3.05
Extreme 3.05
3.38
1 month 2.9
Extreme 2.9
3.97
Current year 1.8
Extreme 1.8
4.72
1 year 1.8
Extreme 1.8
4.72
3 years 0.72
Extreme 0.72
13.18
5 years 0.72
Extreme 0.72
13.18
10 years 0.72
Extreme 0.72
13.18
Manager TitleAgeSince
Chief Executive Officer 56 01/01/2011
Director of Finance/CFO 57 01/12/2022
Chief Tech/Sci/R&D Officer - 02/02/2026
Director TitleAgeSince
Chairman 56 -
Director/Board Member 44 15/05/2023
Director/Board Member 68 30/11/2020
Date Insider Type Main position Quantity % Market Cap. Importance
30/04/26 Other

Director

1,800,000 0.3151%
01/04/26 Other

Chief Executive Officer

8,325,618 1.4572%
01/04/25 Other

Chief Executive Officer

3,960,550 0.7694%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+0.33%-8.88% - 224M
-1.79%-2.27%+50.90%+89.03% 67.98B
-2.06%-0.18%+41.53%+88.17% 64.94B
-0.31%+6.54%-11.39%+457.82% 27.58B
-3.00%-2.90%+39.40%+9.41% 25.74B
+0.86%+1.65%+0.25%-14.78% 26.06B
-1.46%+0.42%+24.07%-18.70% 20.09B
-2.96%-15.21%+210.71%+370.84% 17.16B
-1.49%-4.88%-0.41%+530.26% 14.92B
-0.20%+8.37%+57.87%+159.50% 14.62B
Average -1.24%+0.26%+40.41%+185.73% 27.93B
Weighted average by Cap. -1.52%+0.18%+42.25%+145.08%

Financials

2024 2025
Net sales - -
Net income -382M -446M -56.87M -48.93M -46.04M -42.06M -78.68M -5.37B -78.89M -544M -211M -2.75B -214M -209M -8.87B -245M -286M -36.49M -31.4M -29.54M -26.99M -50.48M -3.45B -50.62M -349M -135M -1.77B -137M -134M -5.69B
Net Debt -413M -482M -61.49M -52.91M -49.78M -45.47M -85.07M -5.81B -85.3M -588M -228M -2.98B -231M -226M -9.6B -376M -439M -56M -48.19M -45.34M -41.42M -77.48M -5.29B -77.69M -536M -208M -2.71B -210M -206M -8.74B
Logo HighTide Therapeutics, Inc.
HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The Company has developed a product pipeline of multiple product candidates in-house, covering many indications in metabolic and digestive diseases among which, some are at clinical-stage. The Company’s core product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases. The Company conducts operations in the United States, Mainland China, Hong Kong and Australia.
Employees
-
Date Price Change Volume
04/09/26 HK$3.080 0.00% 337,500
03/09/26 HK$3.080 -1.91% 105,500
02/09/26 HK$3.140 0.00% 210,500
01/09/26 HK$3.140 -1.26% 155,000
31/08/26 HK$3.180 +3.58% 157,500

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 2511 Stock